India, June 8 -- Immuneel Therapeutics, a Bengaluru-based cell and gene therapy startup, has announced the successful close of its Rs 100 crore plus Series B financing. The round saw participation from new investors including Singularity AMC, Rainmatter by Zerodha, and several High-Net-Worth Individuals alongside strong continued support from existing investors including Kiran Mazumdar-Shaw, Eight Roads Ventures, and F-Prime Capital.

The financing will directly fund key strategic priorities: scaling Immuneel's GMP manufacturing capacity, advancing its next-generation deep-tech cell and gene therapy pipeline toward clinical milestones, supporting the commercialisation of Qartemi, and accelerating international market entry across Asia Pac...